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Abstract
Introduction: The glucocorticoid receptor (GR) plays an important regulatory role in the immune system. Four
polymorphisms in the GR gene are associated with differences in glucocorticoid (GC) sensitivity; the minor alleles
of the polymorphisms N363 S and BclI are associated with relative hypersensitivity to GCs, while those of the
polymorphisms ER22/23EK and 9b are associated with relative GC resistance. Because differences in GC sensitivity
may influence immune effector functions, we examined whether these polymorphisms are associated with the
susceptibility to develop Rheumatoid Arthritis (RA) and RA disease severity.
Methods: The presence of GR polymorphisms was assessed in healthy controls (n = 5033), and in RA patients
(n = 368). A second control group (n = 532) was used for confirmation of results. In RA patients, the relationship
between GR polymorphisms and disease severity was examined.
Results: Carriers of the N363 S and BclI minor alleles had a lower risk of developing RA: odds ratio (OR) = 0.55
(95% confidence interval (CI) 0.32-0.96, P = 0.032) and OR = 0.73 (95% CI 0.58-0.91, P = 0.006), respectively. In
contrast, 9b minor allele carriers had a higher risk of developing RA: OR = 1.26 (95% CI 1.00-1.60, P = 0.050). For
ER22/23EK minor allele carriers a trend to an increased risk OR = 1.42 (95% CI 0.95-2.13, P = 0.086) was found. All
ER22/23EK carriers (32/32) had erosive disease, while only 77% (259/336) of the non-carriers did (P = 0.008). In
addition, ER22/23EK carriers were treated more frequently with anti-tumor necrosis factor-alpha (TNFa) therapy
(P < 0.05).
Conclusions: The minor alleles of the 9b and ER22/23EK polymorphisms seem to be associated with increased
predisposition to develop RA. Conversely, the minor alleles of the N363 S and BclI polymorphisms are associated
with reduced susceptibility to develop RA. These opposite associations suggest that constitutionally determined GC
resistance may predispose to development of auto-immunity, at least in RA, and vice versa.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease in which dysregulation of the immune system
plays a central role. However, some parts of its etiology
remain largely unknown. Several lines of evidence sug-
gest that dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis may play a contributory role in the
pathogenesis of RA [1]. In Lewis rats, used as animal
model for chronic arthritis, an impaired HPA-axis activ-
ity is clearly associated with the development of chronic,
erosive arthritis, which can be antagonized by adminis-
tration of dexamethasone [2]. In patients with RA,
plasma adrenocorticotropic hormone and cortisol levels
are relatively low despite the presence of severe inflam-
mation and high IL-6 levels, a major HPA-axis stimulus
during inflammation [3]. In addition, the number of glu-
cocorticoid receptors (GRs) in RA patients was signifi-
cantly lower than in controls and the cortisol response
to surgical stress is attenuated in patients with RA [4,5].
These observations suggest that a blunted HPA-axis is a
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of RA.
Apart from the glucocorticoid (GC) concentration, the
ultimate biological effects of GCs are also determined by
an individual’s GC sensitivity. GCs exert their effects by
binding to the GR. Population studies identified several
polymorphisms in the GR gene, on chromosome 5,
which are associated with differences in GC sensitivity
[6,7]. The minor alleles of the GR polymorphisms N363
S (rs6195) and BclI (rs41423247) are associated with a
relative hypersensitivity to GCs. The N363 S polymorph-
ism (identified in codon 363 of exon 2) is located in the
part of the GR gene that encodes the GR transactivating
domain [6]. The BclIp o l y m o r p h i s mi sa ni n t r o n i c
restriction fragment length polymorphism located 646
bp downstream from exon 2 [8]. Carriers of the minor
alleles of the N363 S and BclI polymorphisms have
lower cortisol levels after administration of low-dose
dexamethasone compared with non-carriers of this allele
and have phenotypic features reminiscent of endogenous
hypercortisolism such as an increased body mass index,
abdominal obesity, increased insulin response and
depression [8,9].
In contrast, the minor alleles of the ER22/23EK
(rs6189 and rs6190) and 9b (rs6198) polymorphisms are
both associated with a relative GC resistance [10,11].
The ER22/23EK polymorphism is also located in the
part of the GR gene that encodes the transactivating
domain and consists of two linked single nucleotide
mutations in codons 22 and 23 in exon 2 [6]. The 9b
polymorphism is located in exon 9b and is thought to
increase the stability of the GR splice variant GRb,
w h i c ha c t sa sad o m i n a n ti n hibitor of the functional
wild-type GRa [12]. Carriers of the minor alleles of the
ER22/23EK polymorphism show a decreased response
to the administration of 1 mg dexamethasone [7,10].
Furthermore, carriers of the minor alleles of ER22/23EK
tend to have a beneficial metabolic profile, reflected by
significantly lower fasting insulin levels, lower choles-
terol levels, and lower high-sensitive C-reactive protein
l e v e l s ,a sw e l la saf a v o r a b l eb o d yc o m p o s i t i o na n d
decreased risk of dementia [13-15]. The GR polymorph-
ism 9b was found to be associated with RA in a small
group of patients, as well as with a reduced risk for Sta-
phylococcus aureus nasal carriage in healthy subjects,
which may indicate reduced GC-induced immunosup-
pression [16,17].
As GR polymorphisms may modulate GC responsive-
ness of the immune system, we hypothesize that poly-
morphisms in the GR gene, which are accompanied by
relative GC hyper- and hyposensitivity, are associated
with a decreased or increased susceptibility to develop
RA, respectively. To further explore possible involvement
of genetically determined GC sensitivity in RA, we
examined the prevalence of these polymorphisms as well
as the relation with disease severity in a well-defined
population of patients with severe RA and controls.
Materials and methods
Participants
Three-hundred and sixty-eight Caucasian patients who
met the American College of Rheumatism 1987 criteria
[18] were included in the study. Additionally, all patients
had to be either rheumatoid factor positive, anti-cyclic
citrullinated peptide (CCP) positive, or have joint erosions.
Radiographic assessment of the joints was used to esti-
mate the presence of joint erosion consistent with RA.
In 97% of the RA patients (n = 357) radiographic data
were available. Anti-CCP test data were available in 34%
of patient (n = 125).
The use of anti-TNFa therapy was used as a marker
of disease severity. In the Netherlands this therapy is
only prescribed and reimbursed by health insurance
companies for RA patients with therapy-resistant dis-
ease. Therapy-resistance is defined as failure of at least
two disease-modifying anti-rheumatic drugs (DMARDs),
including methotrexate, and still active disease (defined
as disease activity score using 28 joint counts > 3.2)
despite therapy with methotrexate 25 mg weekly or with
methotrexate at the maximum tolerated dose. Approxi-
mately 32% of the RA patients (n = 117) were treated
with anti-TNFa therapy.
The study was approved by the local ethics committee.
Written informed consent was obtained from all
participants.
Controls
Participants of the Rotterdam Study were used as a con-
trol group. The Rotterdam Study is a (Caucasian) popu-
lation-based cohort study, designed to study the
frequency and determinants of chronic diseases in the
elderly. All inhabitants of Ommoord, a suburb of Rot-
terdam, the Netherlands, aged 55 years and over were
invited, of whom 7,983 participated in this study [19].
Participants were excluded from this control group if
they reported to be diagnosed with RA, or reported the
use of anti-inflammatory and anti-rheumatic drugs or
immunomodulating agents. A total of 5,033 participants,
who met the inclusion criteria and were completely gen-
otyped, was included in the control group.
A second control group consisting of 532 healthy
volunteer blood donors, of whom only age and sex were
known, was used for comparison and confirmation of
the results.
DNA extraction and genotyping
On enrollment in the study, blood was drawn from each
patient and DNA was extracted from fresh blood
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genotyped for the functional GR polymorphisms N363 S
(rs6195), BclI (rs41423247), ER22/23EK (rs6189 and
rs6190) and 9b (rs6198). Genotyping was performed
using the allelic discrimination technique, with custom
designed primers and probes (Assay by Design service,
Applied Biosystems, Nieuwerkerk aan den IJssel, The
Netherlands, primer and probe sequences available on
request), using TaqMan Universal PCR master mix
(Applied Biosystems, Nieuwerkerk aan den IJssel, The
Netherlands). Reaction components and amplification
parameters were based on the manufacturer’s
instructions.
Statistical analysis
All analyses with regard to the differences between cases
and controls were performed using a binary logistic
regression model. Crude odd ratios (OR), as estimates of
the relative risks, were calculated with 95% confidence
intervals (CI), and accordingly expressed with lower and
upper bounds. For all four polymorphisms, ORs were
calculated from the proportion of minor allele carriers
in cases and controls. Additionally, for the Bclla n d9 b
polymorphisms, ORs were computed for homozygous
and heterozygous carriers of the minor alleles, sepa-
rately. This subdivision was not applied to the ER22/
23EK and N363 S carriers because of their lower preva-
lence. The computations were repeated with adjustment
for sex and age, by implementing the variables in the
model.
Analyses for binary disease parameters, that is anti-
TNFa therapy use, medication use, and radiographic
joint erosion, were performed using a binary logistic
regression model. In case of a continuous disease para-
meter, that is number of medications per disease year, a
general linear model was used. These analyses were also
performed with adjustment for age and sex by multivari-
able modelling.
The presented P values are two-sided throughout, and
a P < 0.05 was considered statistically significant. Data
were analyzed using SPSS for Windows, release 12.0.1
(SPSS, Chicago, IL, USA).
Results
Patients and controls
For 368 RA patients, a complete data set on disease
parameters, confounding variables and GR genotypes
was available. Two control groups were studied, the first
consisted of 5,033 participants of the Rotterdam study,
and the second group consisted of 532 healthy blood
donors. Table 1 presents the baseline characteristics for
case and control groups. Both age and sex were signifi-
cantly different between the groups (P < 0.01). Rheuma-
toid factor was present in 91% of the RA patients. Anti-
CCP was present in 83% of the RA patients who were
tested. The median number of DMARDs used per dis-
ease year was three. Anti-TNFa compounds were admi-
nistered to 117 of 364 patients.
Genotype frequencies for all polymorphisms in both
control groups were in Hardy-Weinberg Equilibrium.
The BclIa n d9 b carriers are subdivided into heterozy-
gous and homozygous carriers. Between both control
groups, no significant differences were found in the pre-
valence of all four polymorphisms.
Case-control associations
The prevalence of GR polymorphisms was assessed in
RA patients and compared with the prevalence among
participants of the Rotterdam study. After adjustment
for the possible confounding factors age and sex, three
out of four polymorphisms showed a significant associa-
tion with RA (Table 2). Carriers of the N363 S and BclI
minor alleles had a lower risk of developing RA: OR =
0.55 (95% CI = 0.32 to 0.96, P = 0.034) and OR = 0.73
(95% CI = 0.58 to 0.91, P = 0.006), respectively. In con-
trast, the minor allele of the 9b polymorphism was asso-
ciated with an increased risk of developing RA: OR =
1.26 (95% CI = 1.00 to 1.60, P = 0.05). For ER22/23EK
minor allele carriers also an increased risk OR = 1.42
(95% CI = 0.95 to 2.13, P = 0.086) was found, although
not significant.
T h eo u t c o m e sw e r ev e r i f i e db yc o m p a r i n gt h ep r e v a -
lence of GR polymorphisms in the group of RA patients,
with the second control group of healthy blood donors
(Table 3). Once again BclI carriers showed a lower risk
of developing RA (OR = 0.61, 95% CI = 0.43 to 0.86, P
= 0.005), as did the N363 S carriers (OR = 0.71, 95% CI
Table 1 Baseline characteristics of the RA patients
population and two control populations
RA
n = 368
Rotterdam
study
n = 5033
Blood
donors
n = 532
Mean age (SD) 59.5 (15.2) 68.7 (8.8) 42.7 (7.8)
Gender (% female) 73.4 57.6 45.1
Median disease
duration
8.5 (0-54)
Anti-CCP positive* 104/125
(83.2%)
RF positive 336/367
(91.6%)
Erosion 291/357
(81.5%)
Median nr DMARDs 3 (1-13)
Anti-TNFa use 117/364 (32%)
* anti-CCP was not routinely analysed.
CCP, cyclic citrullinated peptide; DMARDs, disease-modifying anti-rheumatic
drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation;
TNF, tumor necrosis factor.
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the 9b polymorphism demonstrated an increased risk of
developing RA (OR = 1.44, 95% CI = 1.00 to 2.07, P =
0.049), just like the ER22/23EK carriers (OR = 1.54, 95%
CI = 0.82 to 2.90, P = 0.181). These results are
consistent with the effects found when compared with
the first control group.
Using the program Phase (version 2.1, Matthew Ste-
phens Lab, University of Chicago, Chicago, IL, USA), we
reconstructed the haplotypes for these populations
Table 2 Frequencies of GR polymorphisms in RA patients vs. controls from the Rotterdam study, adjusted for age and
sex
Polymorphism RA
Case, n (%)
Rotterdam study
Control, n (%)
Unadjusted
OR (95% CI)
P-value Adjusted
OR (95% CI)
P-value
ER22/23EK
Non-carriers 336 (91.3%) 4721 (93.8%) reference reference
Carriers 32 (8.7%)
1 312 (6.2%)
2 1.44 (0.99-2.10) 0.058 1.42 (0.95-2.13) 0.086
N363S
Non-carriers 352 (95.7%) 4664 (92.7%) reference reference
Carriers 16 (4.3%) 369 (7.4%)
3 0.58 (0.35-0.95) 0.032 0.55 (0.32-0.96) 0.034
BclI
Non-carriers 176 (47.8%) 1979 (39.3%) reference reference
Carriers* 192 (52.2%) 3054 (60.7%) 0.71 (0.57-0.87) 0.001 0.73 (0.58-0.91) 0.006
Heterozygous carriers 149 (40.5%) 2370 (47.1%) 0.71 (0.56-0.89) 0.003 0.72 (0.57-0.92) 0.008
Homozygous carriers 43 (11.7%) 684 (13.6%) 0.71 (0.50-0.996) 0.047 0.74 (0.52-1.07) 0.108
9b
Non-carriers 233 (63.3%) 3445 (68.4%) reference reference
Carriers* 135 (36.7%) 1588 (31.6%) 1.26 (1.01-1.57) 0.041 1.26 (1.00-1.60) 0.050
Heterozygous carriers 124 (33.7%) 1437 (28.6%) 1.28 (1.02-1.60) 0.035 1.13 (1.004-1.62) 0.047
Homozygous carriers 11 (3.0%) 151 (3.0%) 1.08 (0.58-2.00) 0.816 1.08 (0.58-2.22) 0.720
1 One homozygous carrier.
2 Eight homozygous carriers.
3 Four homozygous carriers.
* This includes hetero- and homozygous carriers.
CI, confidence interval; GR, glucocorticoid receptor; OR, odds ratio; RA, rheumatoid arthritis.
Table 3 Frequencies of GR polymorphisms in RA patients vs. blood donor controls, adjusted for age and sex
Polymorphism RA Case, n (%) Blood donors Control, n (%) Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
ER22/23EK
Non-carriers 336 (91.3%) 495 (93.0%) reference reference
Carriers 32 (8.7%)
1 37 (7.0%)
2 1.27 (0.78-2.08) 0.335 1.54 (0.82-2.90) 0.181
N363S
Non-carriers 352 (95.7%) 493 (92.7%) reference reference
Carriers 16 (4.3%) 39 (7.3%) 0.58 (0.32-1.04) 0.066 0.71 (0.34-1.50) 0.380
BclI
Non-carriers 176 (47.8%) 199 (37.4%) reference reference
Carriers* 192 (52.2%) 333 (62.6%) 0.65 (0.50-0.85) 0.002 0.61 (0.43-0.86) 0.005
Heterozygous carriers 149 (40.5%) 255 (47.9%) 0.66 (0.50-0.88) 0.004 0.63 (0.44-0.92) 0.015
Homozygous carriers 43 (11.7%) 78 (14.7%) 0.62 (0.41-0.95) 0.028 0.53 (0.31-0.92) 0.024
9b
Non-carriers 233 (63.3%) 367 (69.0%) reference reference
Carriers* 135 (36.7%) 165 (31.0%) 1.29 (0.97-1.71) 0.076 1.44 (1.001-2.07) 0.049
Heterozygous carriers 124 (33.7%) 147 (27.6%) 1.33 (0.995-1.78) 0.054 1.52 (1.05-2.22) 0.028
Homozygous carriers 11 (3.0%) 18 (3.4%) 0.96 (0.45-2.04) 0.992 0.85 (0.32-2.27) 0.746
1 One homozygous carrier.
2 One homozygous carrier.
* This includes hetero- and homozygous carriers.
CI, confidence interval; GR, glucocorticoid receptor; OR, odds ratio; RA, rheumatoid arthritis.
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haplotypes did not result in different ORs (data not
shown) [20,21].
Severity of disease
We used three different parameters to assess the severity
of disease, namely erosive disease, the use of anti-TNFa
therapy and number of medications used per disease year.
ER22/23EK carriers were treated more frequently with
anti-TNFa therapy: OR = 2.90 (95% CI = 1.08 to 7.80, P
= 0.035). None of the other polymorphisms showed a
significant association with erosive disease or anti-TNFa
therapy. All ER22/23EK carriers (32 of 32) had erosive
disease, whereas only 77% (259/336) of the non-carriers
did (P = 0.008). However, it should be noted that in
some patients X-rays were per f o r m e do n l ya td i a g n o s i s
and it is likely that in patients who have more severe
disease, X-rays were performed more often, increasing
the chance of finding erosion.
To assess the number of medications per disease year
we selected patients who had a disease duration of more
than five years. This was performed to correct for the
fact that at present it is more common to treat newly
diagnosed patients with initial combination therapy and
to change DMARDs more frequently in case of inade-
quate response. This can distort a possible association
between the number of medications and the GR poly-
morphisms. A total of 257 patients was eligible to assess
the association between GR polymorphisms and number
of medications per disease year, but no significant asso-
ciation with any of the GR polymorphisms was found.
Discussion
In this study we examined whether functional poly-
morphisms of the GR gene are associated with RA
susceptibility. We show that carriers of GR polymorph-
isms associated with increased GC sensitivity (the minor
alleles of the N363 S and BclI polymorphisms) have a
lower risk of developing RA, in contrast to carriers of
GR polymorphisms associated with relative GC resis-
tance (the minor alleles of the ER22/23EK and 9b poly-
morphisms) who were overrepresented among RA
patients. These opposite associations may point to a
contributory role for GC sensitivity in the susceptibility
to develop RA.
The pathogenesis of synovial inflammation in RA is
complex and involves development of autoreactivity
with an important role for T-cell activation, auto-antibo-
dies, proinflammatory cytokines and specific HLA-DR
genes as genetic predisposing factors [1]. Apart from
enhanced proinflammatory pathways, attenuation of
anti-inflammatory mechanisms may play a contributory
role in the development of auto-immunity. Defects in
the HPA-axis with a concomitant decreased endogenous
immunosuppression have been implicated in RA [2,3,5].
In addition to a relatively low cortisol concentration,
changes in GC sensitivity could be involved in the
pathogenesis of RA. GCs act via the GR and after bind-
ing of GC this ligand-bound complex translocates into
the nucleus where it can either bind to GC responsive
elements or directly to transcription factors. This results
in upregulation (’transactivation’)o rd o w n r e g u l a t i o n
(’transrepression’) of target gene transcription. Immuno-
suppressive effects of GCs are mainly mediated by direct
protein-protein interaction where the GR functions as a
transcription factor leading to transrepression of genes
encoding for, for example, cytokines and proinflamma-
tory transcription factors [22]. GC sensitivity is deter-
mined by both acquired and genetic factors. Acquired
factors include disease-related factors such as cytokines,
Figure 1 Polymorphisms in the glucocorticoid receptor gene and the deduced haplotypes. Position of the polymorphisms are indicated in
relation to the gene (top, not drawn to scale) and the sequence changes and the haplotypes and their frequencies are shown (bottom).
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tory areas, whereas genetic factors involve functional GR
polymorphisms that modulate GC sensitivity, as well as
other variants that may affect the activity of the HPA
axis [23].
In this study we explored the involvement of geneti-
cally determined GC sensitivity in RA. Frequencies of
the minor alleles of the GR polymorphisms that are
associated with GC hypersensitivity (BcII and N363 S, 7-
9) were significantly lower in RA patients compared
with healthy controls, which indeed might imply that
carriers of these polymorphisms are less prone to
develop RA. In contrast, frequencies of the minor alleles
of GR polymorphisms associated with a relative resis-
tance to GCs (ER22/23EK and 9b, 10,11,16,17) were
substantially higher in the RA group compared with
healthy controls. However, the results for ER22/23EK
carriers were not significant at the employed significance
level of 5%, which may be due to the low frequency of
this polymorphism in the general population. When a
one-sided test was used, which could be appropriate
because we assume that relative GC resistance leads to
an increased susceptibility to RA, the results were signif-
icant. On the other hand, it is difficult to assess the
influence of the 9b polymorphism (which is always pre-
sent in combination with ER22/23EK, see Figure 1 hap-
lotype 3) in this case.
In this study significant differences were present in
mean age and gender ratio between the RA patients and
controls. These can lead to a confounding bias, causing
an over- or underestimation of the effects in question.
However, based on what is currently known about the
relation between age and sex and GR polymorphisms, it
is unlikely that these differences are relevant with regard
to the observed frequencies of GR polymorphisms. Only
for the ER22/23EK polymorphism, sex-related and age-
related differences have been reported. In young adults
this polymorphism appeared to be associated with sex-
specific differences in body composition and in elderly
men carriers of the ER22/23EK polymorphism had a
better survival compared with non-carriers [13,14]. Yet,
to control for the possible role of confounding bias in
this study, we adjusted all analyses for age and sex by
multivariable modeling. In addition, a second control
group consisting of healthy blood donors was used for
comparison of results. Adjustment for both age and sex
gave no significantly different results in any of the GR
polymorphisms. Furthermore, frequencies of the four
GR polymorphisms were comparable in the two control
groups, which differed significantly in mean age (Table
1 ) .B a s e do nt h e s ef i n d i n g sw ec o n c l u d et h a tt h e
observed associations between the four investigated GR
polymorphisms and RA are unbiased with respect to age
and sex.
With respect to the 9b polymorphism our results are a
confirmation of the findings of DeRijk and colleagues
who studied the prevalence of this polymorphism in a
small group of 30 RA patients [16]. They showed that
there were significantly more 9b carriers in the group of
RA patients compared with a control group. Lee and
colleagues studied the prevalence of the GR polymorph-
ism BclI in a group of 149 Korean RA patients, but
found no significant difference between RA patients and
controls [24]. It should be noted that this population is
of different ethnic origin and can thus not be compared
with our study population. Recently, Donn and collea-
gues found no association between RA and the GR poly-
morphisms N363 S, BclI ER22/23EK or 9b in 198
Caucasian RA patients [25]. This might be explained by
a lack of statistical power. In particular to investigate
the polymorphisms with a low prevalence (N363 S and
ER22/23EK) the sample size of this study is relatively
small. The pathogenesis of RA is a result of a complex
interaction between environmental and several genetic
factors. For that reason the contribution of individual
genetic factors is relatively low and therefore genetic
studies on RA should have enough power to detect even
small ORs [26]. In addition, the studied patient popula-
tion in the article by Donn and colleagues may not be
comparable with our study population. No data were
provided on the presence or absence of rheumatoid fac-
tor nor on treatment characteristics, that is the type and
amount of anti-rheumatic medication. The strength of
our patient group is that it is a large homogenous
cohort of patients with severe RA, as can be appreciated
from the fact that more than 90% of patients are rheu-
matoid factor positive and approximately one third of
patients used anti-TNFa therapy. As the general RA
patient population is heterogeneous with respect to
degree of inflammation, the observed association
between RA and GR polymorphisms may only apply to
a subgroup consisting of RA patients with severe disease
activity.
Apart from the association between the polymorph-
isms with susceptibility of disease we also investigated
whether relative GC resistance could possibly lead to an
earlier onset of RA and/or a more aggressive disease
phenotype. Severity of disease was indicated by radio-
graphic joint erosion, number of DMARDs used and the
administration of anti-TNFa therapy. Carriers of the
ER22/23EK polymorphism showed significantly more
joint erosion and were treated more frequently with
anti-TNFa therapy, which suggests that a relative GC
resistant state is related to a more severe disease
phenotype.
In our patient cohort no data were available on treat-
ment response after GC therapy. It might be hypothe-
sized that GR polymorphisms influence the clinical
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future studies.
Conclusions
In conclusion, the GC-resistant polymorphisms ER22/
23EK and 9b are associated with an enhanced predisposi-
tion to develop RA. Conversely, GC hypersensitive poly-
morphisms N363 S and BclI are associated with a reduced
susceptibility to develop RA. These opposite associations
suggest that genetically determined GC sensitivity might
play a role in the development of auto-immunity, at least
in RA. In addition, relative GC resistance, as in the ER22/
23EK polymorphism, may lead to a more aggressive
disease phenotype.
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